Last updated: June 4, 2026
Executive summary
Fosinopril sodium and hydrochlorothiazide are typically sourced through (1) API and intermediate suppliers for combination manufacturing and (2) finished-dose manufacturers for private label and branded generics. The supplier landscape splits by whether you need: (a) the combination tablet (fixed-dose combination, FDC) or (b) standalone APIs to formulate and manufacture FDCs in-house. Patent and regulatory status often drive which manufacturers can legally supply US market products, while sourcing stability and compliance (DMF/CEP, GMP footprint, residuals) drive supplier selection.
Who supplies fosinopril sodium and hydrochlorothiazide APIs for generic combination tablets?
Most market supply comes from API producers that support FDA Drug Master File (DMF) submissions or equivalent dossiers for global regulators. For combination products, the practical buyer categories are generic manufacturers and contract development and manufacturing organizations (CDMOs) that either:
- purchase both APIs and formulate tablets, or
- buy finished oral solid dose tablets and repackage/label.
Common API sourcing categories
API-only suppliers
- Provide fosinopril sodium API and hydrochlorothiazide API.
- Support regulatory filings via DMFs (US) or CEPs/DMF equivalents (EU/other jurisdictions).
Intermediate and conversion suppliers
- Provide key intermediates (for example, fosinopril intermediates) to API manufacturers.
- Less common as direct supplier to generic firms, but present in supply chain mapping.
CDMO-led procurement
- CDMOs buy APIs and hold qualified supplier status.
- Buyers often interact with the CDMO rather than the API producer.
What finished-dose manufacturers supply fixed-dose combinations of fosinopril and hydrochlorothiazide tablets?
Finished-dose tablet suppliers range from branded originators (where applicable) to multiple generic manufacturers that market AB-rated products under US FDA approvals. For combination tablets, selection depends on:
- tablet strength (typical strengths are 10/12.5 mg, 20/12.5 mg, and sometimes other strength pairs),
- regulatory pathway (ANDA),
- quality system maturity,
- packaging and logistics requirements.
How to shortlist finished-dose suppliers
Shortlisting usually targets:
- ANDA holders with multiple lots per year (supply continuity),
- established commercial manufacturing sites (GMP consistency),
- documentation completeness for audits (CoA templates, analytical methods, stability, change control),
- experience with combination stability and cross-contamination controls.
Which suppliers have regulatory-dossier footprints for fosinopril and hydrochlorothiazide?
Regulatory footprint is typically evidenced through:
- FDA DMFs (US API filings),
- EU CEPs and EDQM documentation (or reliance),
- site inspections and inspection outcomes,
- supplier qualification packages (ICH stability protocols, method validation, nitrosamine controls where relevant).
What diligence matters for these two actives
Fosinopril sodium (ACE inhibitor)
- Salt form consistency and impurity profile control
- Residual solvents and process impurities documentation
- Particle size and polymorph control for formulation stability
Hydrochlorothiazide (thiazide diuretic)
- Degradation products and impurity control
- Particle size distribution for tablet blend uniformity
- Metal/contaminant controls and compliance with current impurity guidance
How many API suppliers exist for fosinopril sodium and hydrochlorothiazide, and who are the main global sources?
A complete count and supplier roster requires a marketplace scan of DMFs and global filings tied to specific sites. Without an enumerated dataset of registered DMFs, CEP holders, and commercial sales listings, an accurate number cannot be produced. The operational takeaway for sourcing teams: vendor qualification is usually anchored to DMF authorization (or documented file access) plus site GMP inspection status, not to generic “API supplier” categories.
What are the likely sourcing pathways: API-to-tablet vs finished-dose private label?
API-to-tablet pathway
- You procure fosinopril sodium API and hydrochlorothiazide API.
- You run formulation, blending, compression, coating, and stability.
- You support ANDA CMC with your chosen suppliers and methods.
Finished-dose private label pathway
- You procure finished tablets from an ANDA manufacturer.
- You repackage/label under your own distribution model.
- You reduce CMC and manufacturing validation burden, but add supply contracting and dependency risk.
Cost and timing implications
- API-to-tablet typically offers more control over cost and process IP, but higher upfront CMC effort.
- Finished-dose private label accelerates launch but narrows your flexibility for label and packaging changes.
What supplier risks matter most for these two APIs?
Key supply risks for ACE inhibitors and thiazide diuretics include:
- single-site dependency for one active,
- API batch-to-batch impurity drift,
- regulatory file accessibility delays (DMF letter access timing),
- inspection outcomes for API manufacturing plants,
- logistics and lead time volatility for APIs.
How does US Orange Book status affect which suppliers can sell into the US?
US supply into the US market is constrained by:
- ANDA/market authorization holders who are already approved for AB substitution,
- any applicable patent barriers and exclusivities listed for the reference product(s),
- the ability to legally market during patent and exclusivity windows.
Practically, buyers seeking “suppliers” often map to ANDA holders with a commercial product already cleared for the specific strength and dosage form, rather than raw API vendors that may not support finished commercial distribution.
What patent or exclusivity constraints change sourcing for fosinopril/hydrochlorothiazide combinations?
Sourcing constraints shift with:
- product life cycle stage for the specific strength and dosage form,
- whether the combination is under active exclusivity (marketing authorization status),
- whether any patent list entries affect the ANDA holder’s launch timing for specific filings.
This matters most when buyers seek finished-dose supply that is AB-rated and stable in long-term contracting.
Key Takeaways
- Sourcing typically splits into API suppliers (DMF-supported) and finished-dose manufacturers (ANDA holders with commercial supply).
- Vendor qualification hinges on dossier accessibility (DMF/CEP), GMP track record, impurity control, and consistent solid-state behavior for tablet performance.
- US market supply depends on approved product availability and any patent/exclusivity constraints tied to specific strengths and dosage forms.
FAQs
1) Can I source fosinopril sodium and hydrochlorothiazide from the same API supplier?
Often possible through broad API catalog suppliers, but qualification still requires separate impurity, stability, and DMF accessibility checks for each active.
2) Do CDMOs typically manage API procurement for fosinopril/hydrochlorothiazide tablet manufacturing?
Yes. Many CDMOs procure and manage qualified suppliers as part of their CMC and batch release process.
3) What documentation is usually required from fosinopril sodium API suppliers for ANDA CMC?
Typically CoA, impurity profiles, method descriptions/validation package support, stability protocol inputs, and DMF or authorized reference file access.
4) What are the common tablet formulation challenges for fosinopril plus hydrochlorothiazide?
Blend uniformity, compression behavior, coating compatibility, moisture sensitivity management, and impurity/degradation control over shelf-life.
5) Are there supplier changes that trigger CMC comparability updates for this combination?
Yes. API source, manufacturing site, particle size, polymorph/crystal form, and process changes usually require comparability work and regulatory notification or supplement strategy.
References
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- US Food and Drug Administration. Drug Master Files (DMF) program information.
